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To measure the incidence of typhoid fever and other
febrile illnesses in Bilbeis District, Egypt, we conducted a
household survey to determine patterns of health seeking
among persons with fever. Then we established surveil-
lance for 4 months among a representative sample of
health providers who saw febrile patients. Health providers
collected epidemiologic information and blood (for culture
and serologic testing) from eligible patients. After adjusting
for the provider sampling scheme, test sensitivity, and sea-
sonality, we estimated that the incidence of typhoid fever
was 13/100,000 persons per year, and the incidence of bru-
cellosis was 18/100,000 persons per year in the district.
This surveillance tool could have wide applications for sur-
veillance for febrile illness in developing countries. 
M
easuring the incidence of febrile illness caused by
various pathogens poses a major public health chal-
lenge because hospital-based approaches capture only a
fraction of patients, clinical diagnosis is usually unreliable,
and diagnostic tests are often not available in disease-
endemic countries (1). Consequently, the incidence and
relative importance of the etiologic agents of the febrile ill-
ness remain unknown in many parts of the world. Public
health personnel have insufficient data to make the disease
burden (incidence, illness, and death) estimates to guide
priorities for the use of scarce health resources (2) and to
help refine policy on the empiric management of febrile
patients (3). 
Attempts to measure the incidence of febrile illness
have been hampered by problems associated with surveil-
lance sensitivity and surveillance specificity. Sensitivity is
determined largely by the placement of the surveillance
system within the healthcare system and the completeness
of enrollment of case-patients (Figure). Although conduct-
ing surveillance at the tertiary hospital level is attractive
from the perspective of laboratory capacity and infrastruc-
ture, such surveillance captures only the most severe ill-
nesses in persons who have access to hospital care.
Hospital-based approaches tend to underestimate disease
incidence. Routine door-to-door visits to every household
in a community to identify febrile persons and then collect
diagnostic specimens is highly sensitive but limited by cost
and time considerations (4). Specificity is determined
largely by the diagnostic criteria used in the surveillance
case definition. Syndrome-based surveillance requires no
laboratory capacity, but lacks specificity because the caus-
es of febrile illnesses may be clinically indistinguishable.
Therefore, syndrome-based surveillance frequently results
in classification errors. To maximize specificity, the case
definition for the febrile illnesses under surveillance must
include a positive result from a reliable diagnostic test. 
A sensitive and specific surveillance system that accu-
rately measures the incidence and causes of febrile illness
in a country or region must be able to detect cases as close
as possible to the population level (Figure) and must be
supported by modern laboratory diagnostic capacity.
Because such surveillance is labor-intensive and expensive,
a rapid method that measures incidence and cause in sen-
tinel populations of a country or region over a finite period
of time is needed. Such sentinel surveillance could be
repeated at intervals to detect changing patterns of disease.
We developed a rapid sentinel surveillance tool to
determine the causes and measure the incidence of febrile
illness. We pilot-tested this tool in Egypt, where the Egypt
Ministry of Health and Population and the U.S. Naval
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‡Ministry of Health and Population, Cairo, Egypt Figure. Febrile illness surveillance pyramid.Medical Research Unit No. 3 (NAMRU-3) have recently
collaborated to expand laboratory capacity at district fever
hospitals as part of a plan to strengthen national hospital-
based surveillance for febrile illnesses. Fever hospitals are
tertiary referral centers for persons with suspected infec-
tious disease. By using our surveillance tool in concert
with Egypt’s expanded laboratory capacity, we aimed to
determine the etiologic agent and to measure the incidence
of the leading causes of prolonged fever in Bilbeis District.
Methods
Study Site
Bilbeis District, Sharkia Governorate, Lower Egypt,
was chosen as the study site. Bilbeis District has a popula-
tion of 664,000 and comprises a rural hinterland and cen-
trally located Bilbeis City. Rural Bilbeis District compris-
es scattered villages and hamlets that rely largely on sub-
sistence agriculture. Bilbeis City consists of high-density
single- and multiple-story dwellings. The relatively close
proximity of this district to Cairo provided practical advan-
tages for epidemiologic and laboratory support. 
Household Survey
We conducted a household survey during August 2000
and January 2001 in Bilbeis and neighboring Fakkous
Districts, Lower Egypt. The survey was part of a larger
study that evaluated injection practices in several parts of
Egypt (5). Our goal was to determine patterns of health-
seeking behavior among persons reporting prolonged fever
(self-diagnosed fever >3 days’ duration) in Bilbeis and
Fakkous Districts during the 3-month period before the
interview. The two districts were divided into 40 rural sites
of approximately equal population. Four of the sites were
randomly selected. In these four rural sites, a census was
conducted of all households and household members. The
study team spent 1 week working in each rural site. All
persons living in each household were invited to partici-
pate in the interview by answering a structured question-
naire. If a household member was absent on the day of the
visit, the study team returned at least once during the 1-
week period. For children <10 years of age, the head of the
household was interviewed.
Sentinel Surveillance
We obtained a contemporary census of all district
health services and health providers from the Bilbeis
District Health Office and used the findings of the house-
hold survey to identify categories of health providers who
were seeing patients with prolonged fever. We used data
from the census of district health services and health
providers as the sampling frame from which to select
health providers for the febrile illness surveillance system.
One district fever hospital, 11 fever specialists, and 68 pri-
mary care providers (general practitioners, internal medi-
cine physicians, pediatricians, and rural health unit doc-
tors) were recorded in the contemporary health services
and health provider census of the Bilbeis District Health
Office. We conducted the surveillance from July through
October 2001 at the fever hospital, among the 11 district
fever specialists, and among a random selection of 10
(15%) of 68 other representative health providers. 
During the 4-month study period, all persons of ages >6
months who visited a surveillance health provider in
Bilbeis District with current fever of >3 days’ duration
were invited to participate. After obtaining informed con-
sent from these febrile patients, health providers adminis-
tered a brief questionnaire that captured demographic and
clinical information; blood was collected for culture and
serologic testing. Health providers were given a small
financial incentive to compensate for the additional time
required to enroll patients. Persons <6 months of age were
not included because this group is understood to be at low
risk for typhoid fever, in part because of predominant or
exclusive breastfeeding (4). Ethical approval was obtained
from the Institutional Review Boards of NAMRU-3 and
the Centers for Disease Control and Prevention.
Laboratory Capacity and Methods
We trained healthcare providers on obtaining blood cul-
ture, sterile technique, and needle safety and supplied these
providers with materials for venipuncture and blood cul-
ture. Couriers visited each provider every day to ensure
adequate laboratory supplies and transport laboratory sam-
ples and test results. Microbiology laboratory technicians
at the Bilbeis fever hospital were trained in blood culture
technology and retrained in basic bacteriology. The med-
ical microbiology laboratory was equipped with biological
safety equipment, an incubator, and other materials neces-
sary to process blood cultures and identify bacteria. The
NAMRU-3 bacteriology laboratory in Cairo provided
training, quality control on all samples and bacterial iso-
lates, a reference laboratory, and special test capacity.
The Phase2 bi-phasic blood culture system (PML
Microbiologicals, Wilsonville, OR) was used. We incubat-
ed bottles for 14 days at 35°C and observed them daily for
signs of microbial growth. Growth in broth or on agar pad-
dles was examined by Gram stain and was subcultured to
solid media for identification. Serologic testing for
Brucella spp. was performed by standard tube agglutina-
tion with Brucella abortus antigen (SA Scientific, San
Antonio, TX). 
Incidence Calculations
Incidence was calculated for each examined disease
after accounting for the provider-sampling scheme, test
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account for the provider-sampling scheme were derived
arithmetically by using the provider populations sampled
in our study as the numerator and the provider populations
known from the contemporary census of all district health
services and health providers as the denominator. Because
the sentinel surveillance system included the only district
fever hospital and all district fever specialists, no multipli-
er was applied to cases detected at these sites. However, to
account for sampling, only 15% of primary health
providers in the district, a multiplier of 6.8 was applied to
cases detected among primary healthcare providers. 
Multipliers to account for shortcomings of test sensitiv-
ity were derived by reviewing published systematic studies
of the performance of the diagnosed tests used in our study
compared with standard criterion tests. The sensitivity of a
single blood culture for the diagnosis of typhoid fever has
been estimated as 50% when compared with bone marrow
aspirate culture (6); therefore, a multiplier of 2.0 was
applied to account for blood culture–negative typhoid
fever. Because most brucellosis cases can be detected with
the combination of blood culture and the tube agglutina-
tion assay, no multiplier was applied to account for test
sensitivity for brucellosis. For the purposes of incidence
calculations, test specificity for typhoid fever and brucel-
losis was assumed to approach 100%.
Multipliers to account for seasonal variation in disease
incidence were derived from syndrome- and laboratory-
based febrile illness surveillance systems. Because approx-
imately 45% of typhoid fever occurs from June through
October in Egypt (national syndrome-based surveillance
system for typhoid fever, unpub. 2000), a multiplier of 2.2
was applied to adjust for the whole year. A similar season-
al pattern occurs for brucellosis (national acute febrile ill-
ness surveillance system, unpub. data, 2000) (Table).
Statistical Methods
Data were stored and analyzed with Epi Info version
6.04 (Centers for Disease Control and Prevention, Atlanta,
GA). Incidence calculations were made by using Microsoft
Excel 2000 (Microsoft Corp. Redmond, WA) spreadsheets.
Results
Household Survey
A census of the four randomly selected rural sites
recorded 369 households. Interviews were completed in all
369 randomly selected households. Of the 2,421 persons
eligible for interview in survey households, 363 (15.0%)
could not be interviewed because the participant was
absent during the 1-week survey period. No eligible person
refused to be interviewed. In total, 2,058 (85.0%) of 2,421
eligible persons, or their guardians, were interviewed. Of
persons interviewed, 474 (23.0%) reported having fever of
>3 days’ duration (i.e., prolonged fever) during the previ-
ous 3 months. Of those reporting prolonged fever, 379
(80.0%) sought care from a health provider. Of those seek-
ing care from a health provider, 340 (89.7%) saw a physi-
cian, 32 (8.4%) saw a pharmacist, and 7 (1.8%) saw a
layperson. Of the 340 who saw physicians, 274 (80.6%)
saw a private physician, 36 (10.6%) saw a rural health unit
physician, 19 (5.6%) saw a physician at a district general
hospital, 7 (2.1%) saw a physician working for a health
insurance organization, and 1 (0.3%) saw a physician at
the district fever hospital.
Sentinel Surveillance
In total, 449 patients with prolonged fever were
enrolled at the sentinel surveillance sites. No eligible
patients refused to participate. Salmonella enterica
serotype Typhi (Salmonella Typhi) was isolated by blood
culture from 19 (4.2%) patients. The median age of
patients with typhoid fever was 22 years (range 5–60
years), and 5 (26.3%) patients were female. Brucella spp.
were isolated by blood culture from 15 (3.3%) patients,
and brucellosis was confirmed by positive tube agglutina-
tion assay (titer of >1:160) for another 16 (3.6%). The
median age of patients with brucellosis was 31 years
(range 11–60 years); 12 (38.7%) patients were female.
Escherichia coli and  Hemophilus influenzae serotype b
were each isolated by blood culture from one patient. No
non-Typhi Salmonella serotypes were isolated.
The contamination of blood cultures with skin flora
(e.g., coagulase-negative Staphylococcus, diphtheroids),
resulting from poor sterile technique, was a problem dur-
Emerging Infectious Diseases • Vol. 9, No. 5, May 2003 541
RESEARCH
Table. Incidence estimates for typhoid fever and brucellosis, Bilbeis District, Egypt, 2001 
No. of cases captured by surveillance site type 
Crude (adjusted
a) 
Disease  Fever hospital 
Fever 
specialist 
Primary 
provider  Total 
Test 
sensitivity 
multiplier 
Seasonality 
multiplier  Total cases 
Incidence 
(/100,000) 
Typhoid fever  6.0 (6.0)  13.0 (13.0)  0.0  19.0 (19.0)  2.0  2.2  83.6  12.6 
Brucellosis  15.0 (15.0)  12.0 (12.0)  4.0 (27.2)  31.0 (54.2)  1.0  2.2  119.2  18.0 
aAdjusted for health provider sampling scheme. No multiplier is applied for cases identified at the fever hospital and among fever specialists. A multiplier of 6.8 is 
applied for cases identified among primary providers. ing the early part of the study. Active monitoring and inten-
sive retraining of participating health providers reduced
the blood culture contamination rate from 15% during the
first 2 months of the study to 7% during the second 2
months of the study (p<0.01). 
Of  patients with brucellosis, 26 (87.1%) of 31 were
diagnosed with and treated clinically for typhoid fever. In
total, 302 (71%) of 423 patients were already using an
antimicrobial agent at the time they sought treatment by a
health provider participating in the sentinel surveillance
system. Patients most frequently reported taking amoxi-
cillin and chloramphenicol. However, no significant asso-
ciation was found between current antimicrobial therapy
and yield of pathogens by blood culture.
Incidence Calculations
After we made adjustments to account for the provider-
sampling scheme, test sensitivity, and seasonality, we esti-
mated the annual typhoid incidence rate as 13/100,000 per-
sons and the annual brucellosis incidence rate as
18/100,000 persons. The multipliers and calculations used
to derive these estimates are summarized in the Table.
Discussion
Before our study, the most reliable existing estimates of
the typhoid fever incidence rates in Egypt were established
during typhoid vaccine studies conducted more than two
decades earlier. These studies documented an annual
typhoid fever incidence of 209/100,000 persons in
1972–1973 (7) and of 48/100,000 persons in 1978–1981
(8,9) among school-aged children in Alexandria, Egypt.
Vaccine studies may overestimate typhoid fever incidence
because they may be preferentially conducted in areas of
known high incidence of typhoid and in groups at high risk
of acquiring typhoid fever (e.g., school-aged children).
Our study, conducted among all age groups in a single dis-
trict, showed annual typhoid fever incidence rates that
were lower, at 13/100,000 persons. This finding is consis-
tent with a study design that was not targeted to a high inci-
dence population. A lower typhoid fever incidence may
also be consistent with reductions of other enteric diseases
reported in Egypt, resulting from improved management
of diarrheal disease (10) and the large and growing propor-
tion of persons living in both rural and urban areas who
have access to safe water (11). 
Our study demonstrated that brucellosis was as impor-
tant as typhoid fever as a cause of prolonged fever in
Bilbeis District. Brucellosis has increasingly become rec-
ognized as a public health problem in Egypt, as it has in
Kuwait and other countries in the Middle East. Our esti-
mated annual rate of 18/100,000 persons approaches that
found in Kuwait during the 1980s (12). Because brucel-
losis and typhoid fever have similar signs and symptoms,
brucellosis frequently was misdiagnosed as typhoid fever,
resulting in provision of inadequate antimicrobial therapy. 
Healthcare provider–based surveillance previously has
been used to capture typhoid fever cases for vaccine stud-
ies (13) and to measure typhoid fever incidence (14).
However, such an approach requires that febrile persons
report to the health providers participating in the study
(Figure). We conducted a household survey to assess pat-
terns of health-seeking behavior in Bilbeis District before
implementing surveillance. We improved the efficiency of
this step by integrating questions of health-seeking behav-
ior for febrile persons with an existing population-based
survey (5). The reliability of the household survey data
could be improved by following classic cluster sampling
methods (15,16). One way to achieve this would be inte-
gration with national demographic and health surveys that
use cluster-sampling methods and are conducted at regular
intervals in many developing countries. 
Identifying, assessing, and strengthening a central lab-
oratory capacity is a key foundational step for implement-
ing our surveillance tool. Our sentinel surveillance study
was built on recently expanded laboratory capacity within
Egypt’s district fever hospitals. Others  investigators have
successfully identified, assessed, and strengthened central
laboratory capacity for sentinel hospital-based studies of
febrile illness (17–19). We extended capacity beyond the
tertiary hospital and into the community to determine the
etiologic agents and to estimate the incidence of febrile ill-
ness closer to the population level. 
Several factors must be considered when assessing the
accuracy of this surveillance tool for measuring the inci-
dence of febrile illnesses. The febrile illness surveillance
tool may not capture mild disease. Although mild illness
does not contribute substantially to disease burden, using a
broader case definition for both the household survey and
for the surveillance system might have captured more
cases. For typhoid fever in particular, a broader case defi-
nition might have captured more cases among children <5
years of age who may experience milder illness (4) than
adults. In addition, including infants <6 months of age
would be important for measuring the incidence of infec-
tious diseases that, unlike typhoid fever, occur frequently
in this age group.
That healthcare providers enroll all eligible patients
and use sterile venipuncture technique are vital to the suc-
cess of this tool. We maximized enrollment by using a
financial incentive and controlled blood culture contami-
nation by active monitoring, regular feedback, and retrain-
ing health providers. Although we reduced blood culture
contamination to 7% during the second half of the study,
the overgrowth of contaminants may have prevented us
from recovering pathogens from a proportion of blood cul-
tures. 
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larger informal healthcare sector (e.g., traditional healers,
informal pharmacists) would present challenges. These
challenges would include identifying, training, and main-
taining the participation of all healthcare providers.
Implementing this surveillance system would also be diffi-
cult where a larger proportion of the population lacks
access to any healthcare. Community use of antimicrobial
agents was high among patients enrolled in our study,
reflecting the global epidemic of community antibiotic
abuse (20). Use of an antimicrobial agent before venipunc-
ture is known to reduce the sensitivity of blood culture in
the diagnosis of typhoid fever (6) and other infectious dis-
eases, although we were not able to demonstrate this
reduction with our data. For typhoid fever, we used the
lower rather than higher reported sensitivity in blood cul-
ture to adjust our crude disease rates to account for com-
munity antibiotic use (6,21). In the future, data might be
available to develop multipliers for the impact of antimi-
crobial agent use on blood culture sensitivity for specific
infections. Furthermore, the epidemiology of typhoid fever
within a country is likely to be heterogeneous in both time
and location. Febrile illness surveillance should be repli-
cated in several representative districts before making
inferences about national disease incidence.
Our febrile illness surveillance tool could be applied in
other countries and regions and lends itself to periodic and
rapid implementation in multiple sites. For example, such
sentinel surveillance could be conducted every 5 years in a
region to update disease incidence assessments and to
guide syndrome-based patient management. Potential
applications extend beyond typhoid fever surveillance.
The surveillance tool may provide a solution to the diffi-
culties of measuring disease incidence that are faced for
many causes of febrile illness (22). For example, because
of asymptomatic parasitemia, a febrile event can be reli-
ably attributed to malaria only when other causes of fever
are excluded, a luxury not afforded to primary healthcare
providers in developing countries and seldom available
even in clinical malaria studies. Our model serves as a
platform, whereby conducting additional tests (e.g., thick
and thin blood smears for malaria parasites, acute- and
convalescent-phase serologic tests) might permit the
simultaneous measurement of the incidence of a broad
range of causes of febrile illness. In so doing, the fraction
of febrile illness attributable to various etiologic agents can
be estimated simultaneously for a country or region.
Collecting additional diagnostic specimens (e.g., urine)
would permit the assessment of relevant biomarkers (e.g.,
the level of community antibiotic use) (23,24). The model
likely could be integrated with sentinel surveillance for
diseases such as typhoid, brucellosis, leptospirosis, malar-
ia, and melioidosis, and for a range of viral and rickettsial
diseases. The resulting data could be used to guide appro-
priate local modifications of algorithms for the empiric
management of febrile persons (e.g., the fever module of
the World Health Organization/United Nations Children’s
Fund guidelines for the integrated management of child-
hood diseases), especially in areas with low prevalence of
malaria (25,26). 
In Egypt, the febrile illness surveillance tool will be
assessed in other districts to develop a national picture of
the current incidence and causes of febrile illness. These
data will help Egypt set priorities for spending for control
measures and target specific prevention activities for a
group of diseases that have thus far eluded accurate enu-
meration and standardized comparisons of incidence.
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